MedTrace Logo

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

NCT00963664 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2009-09-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether an outpatient combination of lovastatin and low-to-moderate dose interferon is effective in the treatment of patients with malignant melanoma.

Conditions

Interventions

DRUG

lovastatin

lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals

DRUG

interferon alfa-2b

interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly

Sponsors & Collaborators

  • NeoPlas Innovation

    lead OTHER

Principal Investigators

  • Stephen B. Cantrell, MD · NeoPlas Innovation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963664 on ClinicalTrials.gov